Cornhusker Capital Acts as Exclusive Advisor for Accudial Pharmaceutical in Acquisition of Spinformation®

Share Article

Deal Paves Way for Significant Growth and EBITDA Enhancement of Accudial Pharmaceutical’s Revolutionary Product Offerings

The Spinformation® acquisition immediately allows us to offer enhanced service offerings to both the liquid and non-liquid markets,” said Richard J. Haskins, CFO, EVP & Director of Accudial.

Cornhusker Capital, LLC acted as the exclusive financial adviser to Accudial Pharmaceutical, Inc. (Accudial) in the acquisition of Steven Key Design, LLC, which does business as Spinformation®. Stephen Key, Founder of SKD, will remain with SKD, a wholly owned subsidiary of Accudial, as CEO. The announcement was made by Reginald McGaugh, Founder & Chief Executive Officer of Cornhusker Capital, LLC and the transaction was led by Wendy Muhammed, Cornhusker Capital Senior Managing Director. Terms of the acquisition were not disclosed.

“We truly appreciate the financial advisory services of Cornhusker Capital, especially Reginald and Wendy related to this transaction. The acquisition of Spinformation® allows us to immediately reach the other 90% of the market we could not address with our current product offerings. The Spinformation® acquisition immediately allows us to offer enhanced service offerings to both the liquid and non-liquid markets,” said Richard J. Haskins, CFO, EVP & Director of Accudial. “We look forward to our continued relationship with Cornhusker Capital as we start the process for a growth equity investment.”

Accudial’s products feature a two-part patented label system that allows the caregiver to administer accurate and exact doses of medication. By rotating the top label, weight and dosing information is revealed from the inner label to the consumer. A caregiver can then measure the appropriate dose in the calibrated dosing device, included in the package, without second guessing the dose.

Innovating the way liquid medications are dosed globally, Accudial Pharmaceutical, Inc. is the only brand with a patented rotating weight-based dosing system designed to administer over-the-counter medications safely and effectively. The Children’s Accudial® line of pediatric medications has won several awards, including Product of the Year in Canada in April 2011, the Edison Gold Award in the Consumer Packaged Goods category in April 2011, the PTPA Winner’s Seal of Approval in August 2011, and Frost & Sullivan’s 2011 North American New Product Innovation Award for Pediatric Dosing Devices.

“This acquisition is the perfect fit for Accudial and significantly enhances the market beyond their revolutionary weight based dosing patented processes for OTC Children liquid medications into the markets for non-liquid medications as well,” said McGaugh. “Not to mention the Consumer Packaged Goods (CPGs) markets where this company will be able to enhance space on labels up to 75%. I look forward to our continued involvement with the senior management team and board members of Accudial Pharmaceutical. I have enjoyed my more than a 3 year relationship with Accudial and I have been extremely impressed with the team since they launched their over-the-counter (OTC) products in the Canadian market in 2010.”

About Cornhusker Capital, LLC:
Cornhusker Capital is a U.S. focused investment banking firm that provides financial advisory services including capital raising for both debt and equity, Merger & Acquisition (M&A), Employee Stock Option Plans (ESOPs) and restructuring services for distressed assets. We are highly experienced Investment Bankers and Advisers focusing on the lower end of the middle market. Our sweet spot is typically those companies under $200 Million in Revenue; and greater than $1 Million in Trailing Twelve Months (TTM) earnings before interest depreciation and amortization (EBITDA). Our principals and Advisory Board has more than 100 years of collective deal making experience. Please visit our website at http://www.cornhuskercapital.com

About Accudial Pharmaceutical, Inc.:
Accudial Pharmaceutical, Inc. is changing the way liquid medications are dosed globally. It is the only brand with a patented rotating weight-based dosing system designed to administer over-the-counter medications safely and effectively. Children’s Accudial® is a family of 17 analgesic, allergy, cough and cold pediatric medications available in more than 4,300 pharmacies and stores throughout Canada. Children’s Accudial® was recognized as the 2011 Product of the Year Canada in consumer drug packaging, and voted “consumer’s choice” for new product innovation. For more information, visit productoftheyear.ca. In April, 2011 Children’s Accudial® also won Edison Award in the Consumer Packaged Goods category. For more information about Accudial®, visit us at http://www.accuratedose.com or us at call 561.429.6886.

About Spinformation:
The Spinformation® rotating label is a multi-faceted, interactive solution for industries seeking the benefits of an expanded content label in a new, innovative form. The "spin" label is actually two labels – primary information is displayed on the top label, which also features several windows or clear panels. As the label is rotated, information on the inner label is revealed through the windows. Although the concept is undeniably simple, the spin label satisfies a multitude of desires and may perform a variety of functions, including providing more space for brand information, cross promotion, multiple languages, larger font, and games or giveaways. Unlike other ECLs, who may not be able to withstand constant peeling and unpeeling and begin to look damaged on the shelf, the Spinformation® label may be rotated again and again without incurring any damage. For information regarding the company please visit http://www.spinlabels.com.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

William Berger
Visit website